Disclosed are novel aminoindazole urea derivativesof formula (I), wherein R1, R2, R3, R4,X, and Y have themeanings indicated in claim 1. Said aminoindazole ureaderivatives are SGK inhibitors and can be used for thetreatment of SGK-related diseases and ailments such asdiabetes, obesity, metabolic syndrome (dyslipidemia),systemic and pulmonary hypertension, cardiovasculardiseases, and kidney diseases, more generally for any kindof fibroses and inflammatory processes.